Laurberg Tinne, Tramm Trine, Nielsen Torsten, Alsner Jan, Nord Silje, Myhre Simen, Sørlie Therese, Leung Samuel, Fan Cheng, Perou Charles, Gelmon Karen, Overgaard Jens, Voduc David, Prat Aleix, Cheang Maggie Chon U
a Department of Experimental Clinical Oncology , Aarhus University Hospital , Aarhus , Denmark.
b Department of Pathology , Aarhus University Hospital , Aarhus , Denmark.
Acta Oncol. 2018 Jan;57(1):38-43. doi: 10.1080/0284186X.2017.1401735. Epub 2017 Nov 25.
The study of the intrinsic molecular subtypes of breast cancer has revealed differences among them in terms of prognosis and response to chemotherapy and endocrine therapy. However, the ability of intrinsic subtypes to predict benefit from adjuvant radiotherapy has only been examined in few studies.
Gene expression-based intrinsic subtyping was performed in 228 breast tumors collected from two independent post-mastectomy clinical trials (British Columbia and the Danish Breast Cancer Cooperative Group 82b trials), where pre-menopausal patients with node-positive disease were randomized to adjuvant radiotherapy or not. All patients received adjuvant chemotherapy and a subgroup of patients underwent ovarian ablation. Tumors were classified into intrinsic subtypes: Luminal A, Luminal B, HER2-enriched, Basal-like and Normal-like using the research-based PAM50 classifier.
In the British Columbia study, patients treated with radiation had an overall significant lower incidence of locoregional recurrence compared to the controls. For Luminal A tumors the risk of loco-regional recurrence was low and was further lowered by adjuvant radiation. These findings were validated in the DBCG 82b study. The individual data from the two cohorts were merged, the hazard ratio (HR) for loco-regional recurrence associated with giving radiation was 0.34 (0.19 to 0.61) overall and 0.12 (0.03 to 0.52) for Luminal A tumors.
In both postmastectomy trials, patients with Luminal A tumors turned out to have a significant lower incidence of loco-regional recurrence when randomized to adjuvant radiotherapy, leaving no indication to omit postmastectomy adjuvant radiation in pre-menopausal high-risk patients with Luminal A tumors. It was not possible to evaluate the effect of radiotherapy among the other subtypes because of limited sample sizes.
乳腺癌内在分子亚型的研究揭示了它们在预后以及对化疗和内分泌治疗反应方面的差异。然而,内在亚型预测辅助放疗获益的能力仅在少数研究中得到检验。
基于基因表达的内在亚型分类在从两项独立的乳房切除术后临床试验(不列颠哥伦比亚省和丹麦乳腺癌协作组82b试验)收集的228例乳腺肿瘤中进行,其中绝经前淋巴结阳性疾病患者被随机分配接受或不接受辅助放疗。所有患者均接受辅助化疗,并且一部分患者接受了卵巢去势。使用基于研究的PAM50分类器将肿瘤分为内在亚型:管腔A型、管腔B型、HER2富集型、基底样型和正常样型。
在不列颠哥伦比亚省的研究中,与对照组相比,接受放疗的患者局部区域复发的总体发生率显著更低。对于管腔A型肿瘤,局部区域复发风险较低,辅助放疗使其进一步降低。这些发现在丹麦乳腺癌协作组82b研究中得到验证。将两个队列的个体数据合并,给予放疗相关的局部区域复发风险比(HR)总体为0.34(0.19至0.61),对于管腔A型肿瘤为0.12(0.03至0.52)。
在两项乳房切除术后试验中,当随机分配接受辅助放疗时,管腔A型肿瘤患者的局部区域复发发生率显著更低,这表明对于绝经前高危管腔A型肿瘤患者,不应省略乳房切除术后辅助放疗。由于样本量有限,无法评估其他亚型中放疗的效果。